logo
We should be in a golden age for sleep

We should be in a golden age for sleep

Yahoo2 days ago
For much of history, humans probably got pretty lousy sleep. Prior to the Industrial Revolution, many people slept in the same bed alongside their family in dwellings lacking any temperature control beyond a fire or air ventilation. Those homes were littered with bed bugs, fleas, and lice that not only feasted on their hosts at night but also spread diseases, which — in the absence of modern medicine — kept the infirm awake and suffering. The noises of cities and rural life alike also made sleep difficult, thanks to the all-hours bustling of laborers, horse-drawn carriages, and livestock with whom farmers might've shared a home. 'Because in the winter they generated warmth,' says A. Roger Ekirch, a history professor at Virginia Tech and author of At Day's Close: Night in Times Past.
Nighttime itself was a risk. Slumber left people vulnerable to crime or death from fire or other natural disasters. Some prayers throughout history sought God's protection from the litany of threats adherents encountered in the dark, says Ekirch.
For those who are lucky enough to have access, modern marvels like central heating and air conditioning, comfortable beds, and even Tylenol have all but eliminated many of these barriers to sleep. 'We don't have to worry about the myriad perils to sound slumber and our physical well-being that people did 300, 400 years ago,' Ekirch says.
'We don't have to worry about the myriad perils to sound slumber and our physical well-being that people did 300, 400 years ago.'
Still, sleep doesn't come easily to millions of Americans. Over 14 percent of adults had trouble falling asleep most days in 2020, according to the National Health Interview Survey. Nearly just as many people — 12 percent — have been diagnosed with chronic insomnia, according to an American Academy of Sleep Medicine survey. Among the 33 percent of US adults who get less than seven hours of sleep a night, native Hawaiian or Pacific Islander and Black adults are the most likely to get shorter durations of shut-eye. Those with an annual household income of less than $15,000 are also likely to be sleep-deprived.
Despite seemingly prime conditions for sleep, why do so many suffer from restless nights? The most comfortable bed in the darkest room might not be enough to overcome a mix of environmental, systemic, and behavioral forces preventing quality slumber.
American sleep culture is marked by contradictions.
Anyone who's endured a night of terrible sleep can attest to its importance in cognitive functioning, mood, hunger, and overall health. Yet, many people act in ways that sabotage their hope for a good night's sleep. We stay up later than we should to catch up on work or news or precious free time — what is sometimes called revenge bedtime procrastination. We consume content on our phones so upsetting or attention-grabbing as to prevent our falling asleep, although many of us know by now that screen use an hour before bed results in delayed bedtime and less sleep overall. We settle into bed and realize that late-afternoon coffee or nightcap too close to bedtime has come to collect its vengeance.
Some people innately need more sleep than others, and these so-called long sleepers simply cannot find the time in their busy schedules to devote to 10 hours of slumber. Try as we might to have it all, optimizing our waking hours might come at the detriment of our sleep. 'We're trying to have our cake and eat it, too,' Ekirch says. 'The less time we accord to sleep, the more perfect we want it to be for when we do nod off.'
Ironically, a population of people with no notable sleep issues has turned sleep into a competitive sport, leveraging mouth tape, expensive mattresses, and sleep trackers like the Oura Ring in pursuit of the perfect night's sleep. This fixation on enhancing sleep may actually do more to promote insomnia than peaceful slumber, experts say.
Most disruptions to sleep cannot be blamed on personal choices, though. Parents and other caregivers are among the most sleep-deprived, often contending with their children's inconsistent sleep schedules. And the sleep patterns of shift workers — which account for 20 percent of the US workforce — are dictated by their employers.
The ill effects of poor sleep can negatively impact mental health. The opposite is true, too: Mental distress has consequences for sleep. 'Stress, anxiety, weird work schedules,' says Jessi Pettigrew, a clinical social worker who focuses on sleep disorders, 'can lead to the development of sleep disorders like insomnia or circadian rhythm disorders, which basically means being misaligned with your biological sleep schedule because of social reasons.'
Outside of individual behavior, where we live has a role in sleep.
Not having the ability to control the temperature in your bedroom because you lack effective heating or air conditioning can be a barrier to sleep, Pettigrew says. If you feel unsafe in your environment, you're less likely to get restful slumber, too, she adds. This tends to impact people with housing insecurity, refugees, and those who are incarcerated.
Beyond the bedroom, noise and light pollution from bright street lights and traffic have been shown to interrupt sleep and contribute to insomnia — and those in low-income neighborhoods are more susceptible to these conditions.
'People who live in places with good natural light, green spaces, the ability to control the temperature and light and noise in their environment,' Pettigrew says, 'helps them to sleep better and better regulate their circadian rhythm during the day and sleep at night.'
All of our waking experiences impact our ability to sleep, says Anita Shelgikar, a neurology professor at the University of Michigan Medical School and the president of the American Academy of Sleep Medicine board of directors. And some of those waking experiences may be colored by racism and discrimination. Stress associated with racial discrimination has been linked to poor sleep. Among shift workers, people of color are more likely to work alternating day/night schedules, resulting in disrupted circadian rhythms. 'If that disrupts your sleep enough, that technically qualifies as shift-work sleep disorder,' says Jade Wu, a behavioral sleep medicine psychologist and author of Hello Sleep: The Science and Art of Overcoming Insomnia Without Medications. This disorder is marked by excessive sleepiness, insomnia, or both.
The knock-on effects of altered sleep-wake schedules are profound, ranging from cardiovascular disease and obesity to mood and immune disorders. 'Sleep health disparities disproportionately affect the same populations who suffer from overall health disparities,' Shelgikar says.
Those in rural or low-income areas who generally lack access to healthcare, let alone specialized sleep medicine, may continue to suffer from poor sleep, in addition to any number of physical and mental health conditions. Without individualized care, Shelgikar says, the disparities may only widen.
If you work odd hours or have a fussy baby, hearing the common advice of keeping your room cool and dark and only retreating to bed when you're sleepy can seem trite. Wu suggests identifying the environmental or circumstantial reason you aren't getting restful sleep and doing whatever you can to mitigate it. For those who live in spaces that aren't conducive to sleep — hot bedrooms or the constant wail of sirens all night — there are few things people can do beyond getting a fan or earplugs, Wu says. People with means and flexibility can seek out a doctor specializing in sleep medicine to diagnose potential disorders like insomnia or sleep apnea.
If you work odd hours or have a fussy baby, hearing the common advice of keeping your room cool and dark and only retreating to bed when you're sleepy can seem trite.
But if your conditions for sleep are pretty good and you still struggle to get shut-eye, the key, according to Wu, may be to not obsess over it as much. 'What you see in people with insomnia is that they're trying too hard,' she says. 'They're tracking their sleep too closely. They are perfectionistic about their sleep hygiene and doing things like going to bed too early or trying to take too many naps, trying to achieve a certain number of hours of sleep, or a certain score on their sleep tracker.'
The human body was meant to sleep. And despite all the constructs and complications society throws our way, we still require sleep. Ironically, though, the more we fret over it, the more elusive it can become. As difficult as it seems, the best advice may be to surrender to the circadian rhythm. 'One thing that can help with sleep,' Pettigrew says, 'is just saying, I'm going to trust my body to take care of this.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

How This New Biotech Billionaire Outmaneuvered Merck In China
How This New Biotech Billionaire Outmaneuvered Merck In China

Forbes

time2 hours ago

  • Forbes

How This New Biotech Billionaire Outmaneuvered Merck In China

M ichelle Xia spent a dozen years in research and biotech in the U.S. before relocating back to her native China for a job at American life sciences contract research company Crown Bioscience. It didn't take long for her to realize that patients in her home country needed to wait a much longer time than Americans to get the newest and best medicines. Back then, she says, it took eight to ten years for drugs that had been approved in the U.S. to become available in China. 'There was not much innovation in China' in drug development then, Xia recalls. China was producing copies of U.S. drugs, but with a big lag time. Armed with the ambition to change that and ample industry experience, she launched a biotech company in 2012 with two former Crown Bioscience colleagues and one other cofounder in the southern city of Zhongshan–west of Hong Kong. She took the lead as CEO, chairwoman and president of the startup, which they named Akeso–after a Greek goddess of healing. Now, five years after taking Akeso public on the Hong Kong Stock Exchange, the company's standout lung cancer drug has captured outsized attention in the pharmaceutical world. In a Phase 3 trial in China last year comparing Akeso's drug ivonescimab to Merck's Keytruda–the world's best-selling drug, with nearly $30 billion in 2024 sales–the Akeso drug outperformed Keytruda. The fact that a drug from a little known Chinese firm beat Merck's bestseller has led to a runup in Akeso's shares, which nearly tripled in value in the past year. That has turned 58-year-old Xia into a billionaire–with a $1.2 billion fortune, based on her and her family's 8.5% stake in the company, Forbes estimates. She is one of just nine Chinese women billionaires in healthcare (including two who inherited their fortunes)–and one of 13 self-made women billionaires in healthcare globally. More important to Xia is that her company has been an innovator. For its much-heralded cancer compound, Akeso combined two existing methods into one injectable drug: stimulating the immune system to attack the cancer cells and starving the cancer by cutting off the blood supply to the tumors. 'Usually that strategy [of combining two methods] is significantly ignored,' says Robert Booth, a former senior scientific executive at Roche and other firms and now a board member at Summit Therapeutics, which in 2022 licensed ivonescimab from Akeso for markets including the U.S., Canada, Europe and Japan. 'Michelle wasn't afraid to try that. She is confident in her own scientific judgement.' Akeso's achievements are part of a recent wave of success for Chinese biopharma companies. Nearly one-third of drug candidates licensed by large pharmaceutical firms came from Chinese companies last year, up from zero in 2019, according to research firm DealForma. In April, a U.S. congressional commission, the National Security Commission on Emerging Biotechnology, warned in a report that the U.S. risks losing its edge in biotech–and that the government should put $15 billion in funding over five years to support biotech research and manufacturing. 'Over the past five years, China has transitioned from being a nice to watch market to a central pillar of global biopharma innovation,' PwC's pharmaceutical and life science deals leader Roel van den Akker wrote in May. Some of that progress is fueled by Chinese scientists who studied or worked in the U.S. and then moved back to China– just like Xia did. Xia, who uses her given first name, Yu, in China, grew up in Gansu province in the country's northwest, the daughter of two university-educated engineers. After getting a degree in biochemistry at Sun Yat-sen University in Guangzhou in 1988, she obtained a scholarship and got a doctorate in molecular biology and microbiology from Newcastle University in the U.K. In 1996, she moved to the U.S. to do cancer research in a lab at the University of Louisville, in Kentucky, where she had some friends. Four years later she took a job at Celera Genomics–a company best known for its founder, Craig Venter, and his work on the first draft sequence of the human genome. Summit Therapeutics' board member Booth became chief scientific officer of Celera in 2002 and organized research committee meetings that involved senior scientists, in part to train the younger staff. 'Michelle was probably the most junior scientist to join those meetings. She would ask the most probing questions,' he recalls. Booth also set her to work using a complicated assay–a laboratory test employed in drug development–that had taken four very experienced scientists 10 weeks to get it to work when he was at Roche. 'I expected it to take months, but in two weeks she was producing good, reproducible results,'' he says. 'She was a very accomplished scientist, highly productive, and humble.' She later went on to work at Bayer and two other companies, and while in America obtained U.S. citizenship. Xia put her results-oriented focus to work when she and her Chinese colleagues launched Akeso. At the outset, she and her partners were determined to recruit the best university graduates, so they traveled 50 miles to Guangzhou—home to several good universities—to interview students in a conference room at a hospital where a friend worked, she says via Zoom from China, smiling at the memory. Finding private investors was also difficult at first, but Xia's team initially raised about $3 million from wealthy southern Chinese entrepreneurs. In 2015, Xia heard that pharma giant Merck was looking to license an immunotherapy drug candidate to target a protein called CTLA-4. It turned out that Akeso had one in early stage development. Xia, who had met someone from Merck's business development team at a conference, reached out and ended up arranging a deal to license Akeso's drug candidate to Merck for $200 million. It was the first time a Chinese company licensed a lab-developed protein (called a monoclonal antibody) to a global big pharma firm. 'That was a very good validation for us,' Xia recalls. 'We won [that deal] because of our quality and our speed.' Xia has organized Akeso to emphasize scientific advances, with nearly a third of the company's 3,500 employees working in research and development. 'We focus on science and biology and the most advanced technology,' says Xia. 'I think that makes the difference.' Since it was founded 13 years ago, Akeso has gotten five of its drugs approved by China's regulator–including its Keytruda competitor, ivonescimab. Two more drugs it developed and licensed to other companies in China were also approved. Meanwhile, another of its drugs, to treat a rare form of head and neck cancer called nasopharyngeal cancer, was also approved by the U.S. Food and Drug Administration in April. Revenue for the company is expected to grow 59% this year to nearly $470 million, while it's likely to post a net loss of $27 million, according to analysts at Hong Kong-based CMB International. The biggest factor putting Akeso into the spotlight of global pharma was its development of cancer drug ivonescimab. While Akeso had advanced the drug to Phase 3 trials and had presented promising research at ASCO, the big annual oncology conference, in 2022 big pharma was hesitant to do deals with Chinese companies. Says Ken Clark, a longtime biotech lawyer at Wilson Sonsini Goodrich & Rosati and a board member of Summit Therapeutics, 'All of the pharma companies passed on ivonescimab primarily because they didn't believe the data.' Luckily for Akeso, Summit's co-CEOs Maky Zanganeh and Bob Duggan, both now U.S. billionaires, had instructed their small team that same year to scour the globe for a drug in Phase 3 trials to license. One executive who was originally from China, Fong Clow, suggested looking there, and within months the Summit team had narrowed their focus to Akeso's drug. It turned out that Xia, Zanganeh and Duggan had a common tie: A drug candidate that Xia had worked on at Celera Genomics in the early 2000s was later purchased by Pharmacyclics, Duggan and Zanganeh's previous biotech company. Under their leadership, Pharmacyclics took the drug–called Imbruvica–through to FDA approval in 2013 for treatment of chronic lymphocytic leukemia, the most common form of leukemia. It became a blockbuster, and drug giant AbbVie bought Pharmacyclics for $21 billion in 2015. That connection helped give Xia confidence in Zanganeh and Duggan, both of whom had unorthodox backgrounds for biopharma executives: Zanganeh started as a dentist and Duggan, a serial entrepreneur, had run a cookie company, a needlepoint kit seller and more before investing in a robotic surgical company, where he met Zanganeh. The two teams soon recognized they both had entrepreneurial cultures. 'They found me, and I think it's a perfect fit,' says Xia. Akeso and Summit inked their licensing deal in December 2022, with Summit agreeing to pay $500 million upfront plus up to $4.5 billion in potential milestone payments. (Summit is now conducting its own Phase 3 trials of the Akeso drug in order to get approval from the U.S. FDA.) Xia joined Summit's board the next month. 'From the start, she built a company that could handle every step of drug development—from discovery to manufacturing—all under one roof. This gave Akeso speed, flexibility, and control in an industry where timing is everything,' Zanganeh says via text message. At a lung cancer conference in San Diego in September last year, Akeso announced the results of its head to head Phase 3 clinical trial with Merck's Keytruda for patients with a specific type of lung cancer. The patients on Akeso's drug went a median 11.1 months before the cancer returned, compared to 5.8 months for those taking Keytruda. Akeso's stock jumped 16% on the news the next day. Friends from around China and the U.S. reached out to congratulate Xia. Xia has even bigger goals. Akeso already has more than a dozen drug candidates it developed in clinical trials, and she wants to push the company beyond cancer drugs to pursue treatments for neurodegenerative diseases and autoimmune diseases, particularly as China's population ages. That means investing in new technology and new types of drugs, all with the goal of serving patients. Says Xia: 'We want to join the club and become a great company.' More from Forbes Forbes This AI Founder Became A Billionaire By Building ChatGPT For Doctors By Amy Feldman Forbes How The Healthcare Industry Can Address Delays In Psychiatric Care By Amanda Marlar Forbes Meet India's Self-Made Biologics Brewmaster Billionaire By Amy Feldman Forbes Catalysts In Innovation: A Doctor's Dream Impacts Healthcare By Hansa Bhargava

80 years later, victims of ‘first atom bomb' will soon be eligible for reparations
80 years later, victims of ‘first atom bomb' will soon be eligible for reparations

USA Today

time2 hours ago

  • USA Today

80 years later, victims of ‘first atom bomb' will soon be eligible for reparations

More Americans are now eligible for compensation for health problems linked to radiation exposure from the atomic weapons program. A bright, blinding light flashed above New Mexico's Jornada del Muerto desert at 5:30 a.m. on July 16, 1945. The thunderous roar that followed jolted 14-year-old Jess Gililland awake on the porch of his family's ranch 27 miles away. Gililland didn't know it yet, but the U.S. Army had just detonated the world's first-ever nuclear weapon. In the hours and days after the blast, radioactive dust would begin to coat roofs, clotheslines, crops, animals and the ground near Gililland's family home. As the years passed, almost all his family members and neighbors became sick, often with rare forms of cancer. The federal government never warned them about the bomb test, never evacuated them after the blast, or advised them about the potential health consequences of nuclear fallout. Those who lived downwind of the atom bomb say they've never received much recognition – until now. Eight decades after the Manhattan Project's Trinity Test, generations of New Mexicans' who've suffered health problems from the nuclear fallout will soon be eligible to receive compensation. A measure in the recently enacted Republican tax bill expands the pool of Americans eligible for a program that compensates people who have health problems linked to radiation exposure from the atomic weapons program, including uranium miners and downwinders. The Radiation Exposure Compensation Act, first passed in 1990, previously only applied to people in certain parts of Nevada, Utah and Arizona, but didn't include those who were potentially impacted by the Trinity Test in New Mexico, or living on Navajo lands in Arizona, among other areas. For people in New Mexico's Tularosa Basin, the money will make a world of difference, Gililland's 71-year-old daughter, Edna Kay Hinkle, said. 'The people around here, a lot of them are really poor. They couldn't afford gas to go to Las Cruces or Albuquerque (to get treatment),' said Hinkle, who has also battled multiple types of cancer. 'There's people that it means millions, multi-millions, to them.' The Trinity Test's secret fallout Scientists chose to conduct the Trinity Test at the Alamogordo Bombing Range for the area's relative seclusion and predictable winds, which they believed would limit the spread of radiation over populated areas, according to the U.S. Department of Energy's Office of History and Heritage. Army officers pinpointed where thousands of people lived within the 40-mile radius of the test site and prepared emergency evacuation plans. But they never used them. After the test, the military described the giant blast people saw as an accident involving ammunition and pyrotechnics. The federal government didn't reveal the real cause, even to those in the area who had watched the mushroom cloud, until a month later, when the nation dropped an atomic bomb on Hiroshima. By then, those living near the test site had already ingested the radiated material. In a 2015 letter, a man named Henry Herrera, who was 11 years old at the time of Trinity, recounted watching a cloud of black ash fall across his town, including on the clothing his mother had hung outside to dry in the hours after the explosion. 'This filth landed all over our town (and) covered our village with radiation,' wrote Herrera, who passed away in 2022 at age 87. 'Our water was contaminated because all we had was rainwater from the cistern and ditch water. … Everything we consumed was filled with radiation.' The government publicly downplayed the potential consequences of the nuclear bomb test for people living in the Tularosa Basin, despite internal concerns. Five days after Trinity, physicist Stafford Warren wrote a letter to Army Gen. Leslie Groves explaining that high levels of radiation were found 'near a lot of houses.' Warren suggested future tests be conducted 150 miles away from any populated area. Hundreds of thousands of people lived within the 150-mile radius of Trinity. Years later, a health care provider named Kathryn Behnke wrote to Warren from Roswell, New Mexico, explaining that there were 'about 35 infant deaths' in the city in the month after the atomic test. Warren's medical assistant denied that there might be a connection to the testing in his response back to Behnke. But unpublished data from the New Mexico Health Department showed that infant deaths increased by 38% in 1945, compared with 1946, according to the Bulletin of the Atomic Scientists. Radioactive fallout from the test had landed in high densities across New Mexico and Nevada. Fallout from the more than 100 other nuclear tests the government conducted in the years after reached 46 of the 48 contiguous states, along with Mexico and Canada, according to a 2023 study published by researchers at Princeton University and the University of Colorado Boulder. Thousands eligible for compensation The exact number of people eligible for nuclear-weapons-related radiation compensation across the nation remains unknown. But Tina Cordova, who cofounded the Tularosa Basin Downwinders Consortium, said she estimates upward of 10,000 people have had health impacts related to the Trinity Test. The village of Tularosa alone could generate 'thousands of claims out of a town that has consistently had a population of around 3,000,' Cordova said, noting that generations of people who've moved away still have lingering health problems. Thousands more across other states could be eligible, too. Between 1951 and 1958, the United States conducted 188 nuclear tests out West. At the military's Nevada Test Site, 65 miles north of Las Vegas, dozens of nuclear tests were conducted underground each year between 1963 and 1992, according to the Department of Defense. During roughly the same time frame, nearly 30 million tons of uranium ore were extracted from Navajo Nation lands to build nuclear weapons. An estimated 4,000 Navajo labored in more than 1,000 mines, Navajo Nation President Buu Nygren said. Others lived in close proximity. Today, hundreds of abandoned uranium mines remain on the tribe's land and may still be polluting water sources and exposing residents to harmful radiation, according to the Environmental Protection Agency. Nygren called the expansion of the Radiation Exposure Compensation Act a 'victory' for the Navajo. Much like Trinity downwinders, those living on tribe lands were for decades not eligible for compensation. The original act only included people in specific counties across Arizona, Nevada, and Utah who were present when the atomic testing took place and who developed specific types of cancer. The expansion passed in the Republican tax bill extends benefits to include all downwinders in Utah, New Mexico and Idaho, and more living in Nevada, Arizona, Missouri, Tennessee, Kentucky, and Alaska. Uranium miners in Colorado, New Mexico, Arizona, Wyoming, South Dakota, Washington, Utah, Idaho, North Dakota, Oregon and Texas will also be covered. Bernice Gutierrez, a downwinder who was born in Carrizozo, New Mexico, eight days before the Trinity Test, believes money from the program could be an 'economic boom' for communities that have long suffered from radiation-related health impacts. But she and other downwinders have said there is still more work to be done. The RECA reauthorization leaves out people in some parts of Nevada, Arizona, Montana, Colorado, Guam, Ohio, Pennsylvania and Washington state. The extension is also set to expire in two years, leaving concern that some won't be able to apply in time, Gutierrez said. 'Can you imagine 80 years worth of illness and death in New Mexico?' And we have a two-year time frame in which to gather all these applications?' said Gutierrez, who has more than 40 family members who've experienced what they believe to be radiation-related sicknesses. 'It just doesn't end for us' Downwinders are only eligible for compensation if they lived in one of the affected areas when tests were being conducted between 1945 and 1962. Otherwise, if an eligible person has already passed away, their families may be able to file a claim to receive up to $25,000. The National Cancer Institute in 2020 said it found no evidence transgenerational health effects occurred as a result of the test. The study also said there remain 'great uncertainty in the estimates of radiation doses and number of cancer cases possibly attributable to the test.' But Cordova and other downwinders believe the radiation from the blast mutated their ancestors' DNA, making their children and grandchildren more susceptible to cancers and other diseases. Five generations of Cordova's family have had cancer, dating back to 1955. Her 24-year-old niece was the latest to be diagnosed this year. 'It just doesn't end for us.' Cordova said. 'I always say we bury somebody, and someone else is diagnosed. And that is true and has been true in my family forever.' One of her cousins was diagnosed with a rare brain tumor several decades ago, and traveled around the country to find treatment. He died in October of compounding health problems. Two months later, Cordova said her brother was diagnosed with cancer. 'This is a legacy that we will carry forever. Our bodies bear the remnants of the Trinity bomb.'

Why Coffee Stains Your Mugs and the Best Way to Get Rid of Them
Why Coffee Stains Your Mugs and the Best Way to Get Rid of Them

CNET

time4 hours ago

  • CNET

Why Coffee Stains Your Mugs and the Best Way to Get Rid of Them

Did you know that 73% of Americans drink coffee daily? After water, coffee and tea are two of the most popular drinks in the world. If you're one of the folks who finds it hard to start the day without a freshly brewed cup of joe (or tea), chances are you've seen a stained mug or two, regardless of whether you handwash yours or use the dishwasher. In my family, we have an ongoing joke about how my sister absolutely will not touch a mug with even the faintest coffee stain, even if the cup is clean and even if she's putting coffee back in it. That got me thinking: Why do coffee and tea stain mugs so easily, and why are those stains so hard to remove? To find out, I did some digging and found a handful of surprisingly effective ways to keep coffee mugs, thermoses and coffee pots looking spotless. Here's what I learned. For more stain-removing tips, learn how to remove stains from clothes, how to clean workout clothes and how to clean your running shoes. Why does coffee stain your cups and mugs? It's so frustrating to run your cups and mugs through the dishwater only to find they're still stained at the end of the cycle. Before you throw out that old cup, think of it as a learning opportunity to research why coffee has such powerful staining power. Coffee can stain cups and mugs due to the presence of compounds called tannins, a type of polyphenol that is naturally present in coffee beans. When coffee is brewed, tannins can adhere to the surface of cups or mugs, leading to brown staining over time. Boy_Anupong/Getty Images How to avoid coffee stains in your mugs The best offense is a good defense. To stop stains before they start, it's best to rinse a cup or mug right after use to prevent any stains from setting in. Additionally, coffee stains can be exacerbated by other factors, like the temperature of the coffee, since heat accelerates chemical reactions. The tannin compounds in the hot coffee will more strongly adhere to the cup material. Leaving the coffee in the cup or mug for an extended period also makes stains harder to remove since the tannins will set into the surface of the cup as the coffee cools down. The porosity of the cup material can also impact the likelihood of staining. The more porous the material, the more susceptible it is to absorbing liquids and staining. Plastic, earthenware and stone cups or mugs are generally considered more porous. I recommend purchasing high-quality stainless steel cups or mugs since they're non-porous, making stubborn stains unlikely. Regular cleaning of cups or mugs can help prevent coffee stains from ingraining into the material. Let's review some of the best methods for removing coffee stains. Five methods to remove coffee stains for good The following five methods should remove the coffee stains from your cups once and for all. (Or at least until the next time you drink coffee out of it, in which case, you'll need to repeat these steps.) Method one What you'll need: Baking soda and water. What to do: Create a paste by mixing equal parts baking soda and tap water. Apply the paste to the stained areas of the cup, scrub gently with a sponge or brush, then rinse thoroughly. Method two What you'll need: White vinegar. What to do: Soak the coffee-stained cup in a mixture of white vinegar and water for a few hours. After, scrub the stains with a sponge or brush, and then wash the cup with dish detergent to eliminate the sour vinegar taste and its pungent smell. solidcolours/Getty Images Method three What you'll need: Lemon juice and salt. What to do: Make a mixture of lemon juice and table salt. Gently rub this mixture over the stained areas and then rinse thoroughly. You will want to wash the cup or mug with dish detergent and water afterward to get rid of any lingering lemon taste or smell. Method four What you'll need: Baking soda and white vinegar. What to do: Sprinkle a few teaspoons of baking soda inside the cup or mug, gently pour in white vinegar and allow the mixture to fizz. Once it has fizzled out, scrub the stained areas with a sponge or brush and rinse thoroughly. fcafotodigital/Getty Images Method five What you'll need: Denture cleaning tablets. What to do: Denture tablets clean mugs just as well as they clean teeth. Fill the stained cup with warm water and drop in one denture cleaning tablet, making sure to add enough water to completely cover the coffee stains. Let it sit for a few hours, and then scrub and rinse as with the other methods. As with anything, a little effort and time will go a long way to making your cups and mugs shine. These tips will work on any drinkware material and can even be used for tea stains, too. Feel free to repeat any of the above processes as needed to get the stains out. For more cleaning tips, you can also check out how often you should clean your makeup brushes, and the best way to machine wash your sheets and bedding.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store